Roche flashes new 16-week bispecific AMD data, setting eyes on pair of PhIII trials

cafead

Administrator
Staff member
  • cafead   May 06, 2020 at 12:32: PM
via While Roche awaits results from a pair of large Phase III trials, the Swiss pharma is touting another round of data from a smaller study on its wet macular degeneration (nAMD) bispecific antibody, faricimab.

article source